News for LJPC Stock
Innoviva Completes Acquisition of La Jolla Pharmaceutical
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Innoviva to Acquire La Jolla Pharmaceutical Company
Innoviva to Acquire La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress
Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Corporate Progress
La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2020
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company
Back to Sitemap